Valbiotis
Develops clinically proven, plant-based supplements for metabolic diseases.
ALVAL | PA
Overview
Corporate Details
- ISIN(s):
- FR0013254851
- LEI:
- 969500VP4JBJCF0MOP60
- Country:
- France
- Address:
- RUE PAUL VATINE, 17180 PERIGNY
- Website:
- https://www.valbiotis.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of other food products
Description
Valbiotis is a research and development company that develops and commercializes plant-based dietary supplements for the prevention and management of metabolic diseases. The company's portfolio is centered on its patented "TOTUM" line of active substances, which undergo rigorous clinical trials to validate their efficacy. Key products include TOTUM•63 for reducing blood glucose in prediabetic individuals, TOTUM•448 for cardio-liver health, and TOTUM•854 for managing blood pressure. Valbiotis provides scientifically proven, natural, non-drug solutions and is transitioning from a research-focused model to a commercial-stage enterprise.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-10-15 17:40 |
Valbiotis announces the major success of the INSIGHT clinical study on TOTUM•8…
|
English | 234.2 KB | ||
| 2024-10-15 17:40 |
Valbiotis annonce le large succès de l’étude clinique INSIGHT sur TOTUM•854
|
French | 224.0 KB | ||
| 2024-10-09 17:45 |
VALBIOTIS : Information mensuelle relative au nombre total de droits de vote et…
|
French | 122.5 KB | ||
| 2024-09-12 17:45 |
VALBIOTIS : Information mensuelle relative au nombre total de droits de vote e…
|
French | 131.7 KB | ||
| 2024-09-05 17:40 |
VALBIOTIS : Oral presentation at the 2024 EASD congress
|
English | 554.8 KB | ||
| 2024-09-05 17:40 |
VALBIOTIS SA : Présentation orale au congrès 2024 de l’EASD
|
French | 448.9 KB | ||
| 2024-08-12 08:00 |
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
|
French | 122.3 KB | ||
| 2024-07-11 08:30 |
Valbiotis : Bilan semestriel du contrat de liquidité
|
French | 1011.2 KB | ||
| 2024-07-05 08:30 |
Valbiotis : Information mensuelle relative au nombre total de droits de vote …
|
French | 110.5 KB | ||
| 2024-06-26 08:30 |
Valbiotis - Assemblée générale annuelle mixte du 25 juin 2024
|
French | 195.0 KB | ||
| 2024-06-20 08:50 |
Valbiotis : Information mensuelle relative au nombre total de droits de vote et…
|
French | 111.0 KB | ||
| 2024-06-17 17:40 |
Valbiotis invited to present clinical results at the American Diabetes Associat…
|
English | 273.6 KB | ||
| 2024-06-17 17:40 |
Valbiotis sélectionnée aux 84èmes sessions scientifiques de l’American Diabete…
|
French | 270.0 KB | ||
| 2024-06-04 08:00 |
Valbiotis reaches an agreement to terminate its licensing and supply agreement…
|
English | 223.7 KB | ||
| 2024-06-04 08:00 |
Valbiotis annonce un accord avec Nestlé Health Science actant la fin du contrat…
|
French | 238.7 KB |
Automate Your Workflow. Get a real-time feed of all Valbiotis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valbiotis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valbiotis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-01-17 | N/A | Other | Other | 10,400 | 46,072.00 EUR |
Peer Companies
